AAV9-Mtmr2 gene therapy (X-linked myotubular myopathy) (Audentes Therapeutics/Genethon)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameAAV9-Mtmr2 gene therapy (X-linked myotubular myopathy) (Audentes Therapeutics/Genethon)
Drug Alias NameN/A
ClassificationBiologics
Mechanisms of ActionMyotubularin stimulantsMyotubularin expression stimulants
TargetsMyotubularin
Therapy Area/IndicationsMyopathies, Structural, Congenital
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAudentes Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesGenethonAudentes Therapeutics Inc
Active IndicationsN/A
Inactive IndicationsMyopathies, Structural, Congenital

Other Information

ATC CodeN/A
Related LinksN/A